Report of Foreign Issuer (6-k)

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE  13a-16 or 15d-16

UNDER THE SECURITIES EXCHANGE ACT  of 1934

 

For the Month of March 2017

 

001-37521

(Commission File Number)

 

INTEC PHARMA LTD.

(Translation of registrant’s name into English)

 

12 Hartom Street
Har Hotzvim, Jerusalem 9777512, Israel

(+972) (2) 586-4657

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover

Form 20-F or Form 40-F.

 

Form 20-F  ☒  Form 40-F  ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(l): _________

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7): _________

 

 

EXPLANATORY NOTE

On March 22, 2017, Dr. John W. Kozarich, Chairman of the Board of Intec Pharma Ltd. (the “Company”), presented in the Oppenheimer 27th Annual Healthcare Conference.

A copy of the updated corporate presentation of the Company (incorporating the recent initiation of Phase I trial of Accordion Pill for cannabinoid therapies) is attached hereto as Exhibit 99.1.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

	INTEC PHARMA LTD.
	By:	/s/ Zeev Weiss
		Name: Zeev Weiss Title: Chief Executive Officer

 

Date:  March 23, 2017

 

  

 

EXHIBIT INDEX

Exhibit No.	Description
99.1	Corporate Presentation